Total patient population (n=99) | AAA negative (n=44) | ‘Complexed AAA’ (n=26) | AAA positive (n=29) | |
---|---|---|---|---|
Demographics | ||||
Age, mean (SD), year | 54 (11) | 53 (10) | 55 (12) | 54 (13) |
Sex, female, n (%) | 78 (79) | 33 (75) | 19 (73) | 26 (90) |
Disease status | ||||
Disease duration, median (IQR), year | 10 (5–17) | 8 (3–16) | 12 (5–23) | 12 (6–15) |
Rheumatoid factor positive, n (%) | 76 (77) | 34 (77) | 20 (77) | 22 (76) |
Anti-CCP positive, n (%) | 82 (83) | 37 (84) | 23 (89) | 28 (97) |
Erosive disease, n (%) | 80 (81) | 32 (73) | 22 (85) | 26 (90) |
ESR, median (IQR), mm/h | 22 (11–49) | 21 (9–42) | 22 (12–40) | 36 (12–68) |
C-reactive protein, median (IQR), mg/l | 14 (6–30) | 9 (4–20)† | 16 (8–22) | 22 (8–53)† |
DAS28, mean (SD) | 5.2 (1.4) | 4.9 (1.5)† | 5.0 (1.1) | 5.6 (1.3)† |
(Co) medication | ||||
Prior DMARDs, mean (SD) | 3.2 (1.3) | 3.1 (1.3) | 3.4 (1.3) | 3.2 (1.2) |
Prior biologicals, n (%) | 24 (24) | 7 (16) | 7 (27) | 10 (35) |
Methotrexate use, n (%) | 67 (68) | 39 (89)‡ | 15 (58)* | 13 (45)† |
Methotrexate dose, median (IQR), mg/wk | 22.5 (15–25) | 25 (15–25)† | 22.5 (20–25)‡ | 10 (7.5–22.5)† ‡ |
Prednisone use, n (%) | 35 (35) | 14 (32) | 9 (35) | 12 (41) |
Prednisone dose, median (IQR), mg/day | 5 (5–10) | 5 (4–10) | 7.5 (5–10) | 7.5 (5–10) |
*p=0.007 (Fisher's exact).
†CRP: p=0.006; DAS28: p=0.040; methotrexate use: p<0.001; methotrexate dose: p=0.006 (Mann–Whitney U, Fisher's exact, independent sample t test).
‡p=0.012 (Mann–Whitney U).
AAA, anti-adalimumab antibodies; CCP, cyclic citrullinated peptide; DMARDs, disease-modifying anti-rheumatic drugs; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate.